Compares pregnancy and infant outcomes after Wegovy use in pregnancy
Compares outcomes in pregnant women who took Wegovy with those who did not.
Key facts
- Who runs it
- Novo Nordisk A/S
- Where
- Ann Arbor and Princeton, United StatesSee the 2 sites
- Trial code
- NCT05503927
- U1111-1273-4411
- Registry title
- A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
- Status
- Enrolling by invitation
- People taking part
- 2,701 people, planned
- Started
- 1 Feb 2020
- Expected to end
- 15 Aug 2027
- Type of study
- Observational, 3 groups
- Record updated
- 21 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at women aged 15-50 whose insurance claims show a pregnancy. It compares outcomes for mothers and babies with and without Wegovy exposure.
- Age
- 15 to 50 years
- Sex
- Female only
- Disease stage
- Pregnancy with overweight or obesity. Overweight or obesity must be recorded in the six months before pregnancy, plus at least one weight-related condition for the comparison group.
- Earlier treatment
- Three groups: exposed to Wegovy (injection or tablet), exposed to another anti-obesity medicine, or exposed to neither. Exposure starts from 35 days before conception to the end of pregnancy for Wegovy.
- Biomarker or test result
- A BMI of 30 kg/m^2 or more, or an obesity code, in the six months before pregnancy. Another group has a BMI of 27 kg/m^2 or more but under 30 kg/m^2, plus dyslipidemia, type 2 diabetes or high blood pressure.
Main reasons for not taking part
- Exposure to another GLP-1 receptor agonist from 35 days before conception to the end of pregnancy
- Exposure to both Wegovy and another anti-obesity medicine in that period
- Pregnancies with several infants are left out of the infant outcome analysis
This trial only enrols pregnant participants. The registry sentence this rests on: Evidence of a pregnancy end event on a medical claim (example, live birth, stillbirth, or spontaneous abortion) during the pregnancy identification period (that is, 04 June 2021 - 17 February 2034).
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Evidence of a pregnancy end event on a medical claim (example, live birth, stillbirth, or spontaneous abortion) during the pregnancy identification period (that is, 04 June 2021 - 17 February 2034)
- Date of conception between 04 June 2021 and 06 May 2033 (that is last menstrual period (LMP) 43 weeks prior to the latest pregnancy end date)
- Aged 15-50 and female on the date of the LMP
- Continuous enrolment in the database with medical and pharmacy benefits for at least 6 months prior to the date of conception through 42 days after the pregnancy end date
- Among the pregnancies that meet the inclusion criteria, four main cohorts and two sub cohorts of interest will be identified (two Wegovy-exposed cohorts and two comparison cohorts):
- Wegovy-exposed- for greater than or equal to 1 day of Wegovy exposure from 35 days prior to estimated date of conception to end of pregnancy. Two mutually exclusive cohorts will be identified based on first Wegovy exposure during pregnancy; Wegovy injection-exposed- for greater than or equal to 1 day of Wegovy exposure from 35 days prior to estimated end of pregnancy; Wegovy tablet-exposed- for greater than or equal to 1 day of Wegovy exposure from 35 days prior to estimated end of pregnancy
- Other AOM-exposed- greater than or equal to1 day of phentermine, diethylpropion, benzphetamine, phendimetrazine, orlistat, or bupropion/naltrexone exposure, defined as the following:
- Benzphetamine, diethylpropion, orlistat, or phendimetrazine exposure from one day prior to estimated conception date to end of pregnancy
- Phentermine or bupropion/naltrexone exposure from five days prior to estimated conception date to end of pregnancy
- Cohort with Overweight/Obesity and at least one weight related comorbid condition-
- Greater than or equal to 1 diagnosis code for obesity or BMI greater than or equal to 30 kilogram per meter square (kg/m\^2) on a medical claim during the six month pre-pregnancy period
- Greater than or equal to 1 diagnosis code for BMI greater than or equal to 27 kg/m\^2 or less than 30 kg/m\^2 on a medical claim and greater than or equal to 1 non-diagnostic medical claim for dyslipidemia, type 2 diabetes mellitus, or hypertension during the six month pre-pregnancy period
- No exposure to Wegovy or other AOM during the defined exposure window in pregnancy
- Among Wegovy-exposed and Other AOM-exposed pregnancies, the subset with first trimester exposures will be identified as those with greater than or equal to 1 days of exposure at less than 14 WGA
Who cannot take part
- Pregnancies exposed to other glucagon-like peptide-1 receptor agonist (GLP-1 RA) during the exposure identification window (that is, 35 days prior to estimated conception date through pregnancy end date)
- Pregnancies with exposure to both Wegovy and other AOM during the exposure identification window (estimated conception date - 35 days through pregnancy end date)
- Pregnancies resulting in multiple infants will be excluded from the analysis of infant outcomes
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 50 years old?
Where in United States
- IBM Watson Health™ Truven MarketscanAnn Arbor, United StatesEnrolling by invitation
- Princeton, New JerseyHospital not named in the registryEnrolling by invitation
About the trial
What the trial wants to find out
This is an observational cohort study using administrative insurance claims data. The aim of this non-interventional study (NIS) is to compare maternal, fetal and infant outcomes of women exposed to Wegovy during pregnancy to a reference population not exposed to Wegovy, so that participants and healthcare providers can make informed treatment decisions.
The 3 groups in the trial
- Participants Exposed to Wegovy injection or Wegovy tablet
Pregnant participants exposed to Wegovy injection or Wegovy tablet during the first trimester (T1) (that is, 35 days prior to the estimated conception date through \<14 weeks gestational age \[wGA\]) and their linked infants will be observed in this observational study.
- Participants Exposed to Anti-obesity Medication (AOM)
Pregnant participants exposed to other Anti-obesity Medication (AOM) (phentermine, diethylpropion, benzphetamine, phendimetrazine, orlistat, or bupropion/naltrexone) during the first trimester (start of exposure identification window based on five times the half-life of each AOM through \<14 WGA) and their linked infants will be observed in this observational study.
- Overweight/Obese Participants
Pregnant participants with obesity or overweight and at least one weight-related comorbid condition without exposure to Wegovy injection or tablet or other AOM during pregnancy will be observed in this observational study.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Wegovy® (Semaglutide) Database Study: A Population-based Cohort Study to Investigate Safety Outcomes of Exposure to Wegovy During Pregnancy
- Plain-language title
- Compares pregnancy and infant outcomes after Wegovy use in pregnancyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05503927, who can take part
- Record updated
- 21 July 2026